

White Blood Cell Count to Mean Platelet Volume Ratio Is a Prognostic Factor in Patients with Non-ST Elevation Acute Coronary Syndrome with or without Metabolic Syndrome

Mohammad Reza Dehghani, MD¹, Yousef Rezaei, MD², Sanam Fakour, MD³, and Nasim Arjmand, MD³

¹Department of Cardiology, ²Seyyed-al-Shohada Heart Center, ³School of Medicine, Urmia University of Medical Sciences, Urmia, Iran

Background and Objectives: Leukocyte and platelet have been found to be associated with metabolic syndrome (MetS). We aimed to determine the usefulness of a novel marker named white blood cell count to mean platelet volume ratio (WMR) for predicting outcomes of non-ST elevation acute coronary syndrome (NSTEMI-ACS) with or without MetS.

Subjects and Methods: A total of 331 NSTEMI-ACS individuals (60±12.5 years, 57.4% male) were enrolled and followed for a median of 24 months. MetS was identified using the National Cholesterol Education Program Adult Treatment Panel III criteria.

Results: Patients were divided into two groups: high WMR (WMR≥720) and low WMR (WMR<720). Major adverse cardiovascular events (MACE) and MetS rates were significantly greater in the higher WMR group compared to those in the low WMR group (MACE: 14.3% vs. 25%, $p=0.014$; MetS: 50.9% vs. 75%, $p<0.001$). MetS was diagnosed in 62.2% of patients. MACE incidence in patients with or without MetS was comparable ($p=0.737$). Among MetS individuals, patients in the high WMR group had more MACE than the low WMR group (11.2% vs. 26.5%, $p=0.007$). However, MACE was comparable among non-MetS individuals ($p=0.681$). In multivariable Cox regression analysis, hazard ratios (HR) of MACE incidence for high-WMR in MetS individuals was 2.616 (95% confidence interval: 1.282–5.339, $p=0.008$). However, HR of MACE incidence for high WMR in non-MetS individuals was not significant.

Conclusion: Among NSTEMI-ACS patients without revascularization therapy, elevated admission WMR was associated with an increased risk of developing composite MACE in MetS individuals but not in non-MetS patients. (Korean Circ J 2016;46(2): 229-238)

KEY WORDS: White blood cell count; Mean platelet volume; Acute coronary syndrome; Metabolic syndrome; Inflammation.

Introduction

Acute coronary syndrome (ACS) as a presentation of coronary atherosclerosis is associated with inflammatory mechanisms

involved in the development of atherosclerotic plaque and subsequent rupture and thrombosis.¹⁾ Inflammation-based markers have been used to detect high-risk patients and their prognosis.²⁾ Leukocytes have important roles in inflammatory processes.³⁾ Increased white blood cell (WBC) count has been shown to be a predictor of clinical outcomes of patients with ACS.⁴⁾ Besides leukocytes, platelets have been reported to have substantial effect on the development of cardiovascular events through inflammatory mechanisms.⁵⁾ Mean platelet volume (MPV) as a marker of platelet activation is another inflammatory marker that has been demonstrated to be a prognostic marker in ACS setting.⁶⁾

Metabolic syndrome (MetS) is a combined cardiovascular risk factors phenomenon. It includes visceral obesity, dysglycemia, hypertension, elevated triglycerides, and decreased high density lipoprotein.⁷⁾ MetS has become a serious public health problem due to increases in its prevalence and risk of developing type 2 diabetes mellitus and cardiovascular atherosclerotic diseases.⁸⁾ However,

Received: June 2, 2015

Revision Received: July 14, 2015

Accepted: August 11, 2015

Correspondence: Yousef Rezaei, MD, Seyyed-al-Shohada Heart Center, Urmia University of Medical Sciences, Urmia 5718749441, Iran
Tel: 98-912-623-1864, Fax: 98-443-237-5907
E-mail: yousefrezaei1986@gmail.com

• The authors have no financial conflicts of interest.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

the main mechanism involved in how MetS increases these risks remains to be elucidated.⁸⁾ In terms of the pathophysiology of MetS, inflammation has been reported to be a main factor that leads to the development of MetS and cardiovascular diseases.⁹⁾ Some studies have recently found a relationship between the presence of MetS and elevated WBC count, C-reactive protein, fibrinogen, and interleukin.⁹⁾ Taking into account of the aforementioned evidences, we evaluated the prognostic value of a novel inflammation-based marker named white blood cell count to mean platelet volume ratio (WMR) in non-ST elevation acute coronary syndrome (NSTEMI) patients with or without MetS.

Subjects and Methods

Study design

This study was conducted in a prospective fashion. The study protocol was approved by both local ethics committee of Urmia University of Medical Sciences (UMSU) and our Institutional Review Board in the Seyyed-al-Shohada Heart Center of UMSU, Urmia, West-Azerbaijan province, Iran. Consent forms were obtained from all participants. The prognostic value of complete blood count components in patients diagnosed with ACS was evaluated. A total of 862 consecutive patients admitted to emergency department with a chief complaint of new onset chest discomfort were assessed from August 2012 to March 2013. Patients with ST elevation myocardial infarction (STEMI), non-ACS chest pain, and cases whose data were incomplete for identifying MetS, or follow-up were not available were excluded from this study. Other exclusion criteria included cancer history, inflammatory diseases, autoimmune diseases, infectious diseases, and immunosuppressed. After using the exclusion criteria, a total of 331 NSTEMI patients with complete information were enrolled.

Patient selection and data collection

Patients with new onset chest discomfort were subjected to full examination, cardiac markers (creatinine kinase MB isoenzyme and troponin I), and a standard 12-lead electrocardiogram along with continuous health monitoring in the emergency room. Unstable angina in patients was defined as ischemic symptoms suggestive of an ACS without elevation in troponin with or without electrocardiogram changes indicating ischemia. Non-ST elevation myocardial infarction (NSTEMI) in patients was defined as no ST elevation in electrocardiograms but with an increase in cardiac ischemia markers. The diagnosis of STEMI was identified when a patient had typical ischemic chest pain lasting more than 20 minutes along with one of the following criteria: at least 1 mm ST elevation,

the elevation of cardiac markers at least twice of the maximum normal values. In addition, all new cases diagnosed with NSTEMI underwent diagnostic angiography. To identify MetS patients, the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) criteria¹⁰⁾ were used. Patients were diagnosed with MetS if they had at least three of the following factors: 1) waist circumference >102 cm in men and >88 cm in women; 2) triglyceride level of ≥ 150 mg/dL or taking drugs to reduce its level; 3) high density lipoprotein <40 mg/dL in men and <50 mg/dL in women or taking drugs to increase it; 4) blood pressure $\geq 130/85$ mmHg or taking antihypertensive drugs; and 5) fasting plasma glucose ≥ 100 mg/dL or taking antidiabetic agents. To identify the incidence of major adverse cardiovascular events (MACE), all patients were followed up to December 2014. All patients with unstable angina were given anticoagulants (antiplatelet plus intravenous heparin), β blocker, angiotensin-converting enzyme inhibitors, nitrate, and statin. NSTEMI patients were also treated as unstable angina ones. None of our patients underwent revascularization therapy in the hospital. In order to evaluate complete blood count cells, blood samples were collected upon admission and analyzed within 30 minutes of sampling using an automated blood cell counter (Sysmex, Kobe, Japan).

Patient follow-up

We followed all patients for a median of 24 months (Q1: 23 months; Q2: 25 months). Measured clinical outcomes during follow-up period were: 1) coronary artery stenting; 2) non-fatal myocardial infarction; 3) any cause of death. These end points were considered as composite MACE.

Statistical analysis

WMR value was divided into two groups according to its median value: low WMR group (WMR < 720, n=175) and high WMR group (WMR ≥ 720 , n=156). Patients were compared based on the WMR group. Two subgroup analyses were conducted based on the status of MetS within the WMR group. Continuous variables were reported as either Median (25th and 75th percentiles) or mean \pm standard deviation and analyzed using Mann-Whitney U test or t-test. Categorical variables were reported as number (percentage). Differences between groups were compared using chi-square test. Kaplan-Meier analysis was performed to detect the proportion of patients remaining MACE-free during follow-up among all patients and in those with or without MetS. Log-rank test was used to compare groups by. In addition, multivariate Cox regression analysis was used to estimate the hazard ratios (HR) of composite MACE incidence for elevated WMR. The multivariate Cox regression models were corrected for all baseline characteristics,

Table 1. Baseline characteristics, laboratories, and clinical outcomes in groups according to WMR values

	Total(n=331)	WMR<720(n=175)	WMR ≥720(n=156)	p
Baseline characteristics				
Age (year)	60±12.5	61.2±12	58.8±13	0.089
Gender (male)	190 (57.4)	94 (53.7)	96 (61.5)	0.151
Body mass index (kg/m ²)	28 (24.5, 30.7)	27 (24, 30)	29 (25, 31)	0.049
Waist circumference	96 (88, 107)	94 (88, 105)	98 (89, 110)	0.024
Systolic blood pressure	135 (125, 150)	134 (125, 150)	137 (127, 150)	0.614
Diastolic blood pressure	80 (78, 90)	80 (75, 90)	80 (80, 92)	0.429
NYHA functional class				0.470
Class 1	79 (23.9)	39 (22.3)	40 (25.6)	
Class 2	52 (15.7)	24 (13.7)	28 (17.9)	
Class 3	186 (56.2)	103 (58.9)	83 (53.2)	
Class 4	14 (4.2)	9 (5.1)	5 (3.2)	
Previous medical histories				
Diabetes mellitus	106 (32)	50 (28.6)	56 (35.9)	0.154
Hypertension	198 (59.8)	106 (60.6)	92 (59)	0.767
Dyslipidemia	59 (17.8)	30 (17.1)	29 (18.6)	0.731
Smoking	87 (26.3)	38 (21.7)	49 (31.4)	0.045
Familial history	90 (27.2)	47 (26.9)	43 (27.6)	0.885
Myocardial infarction	86 (26)	47 (26.9)	39 (25)	0.701
CABG	41 (12.4)	21 (13.5)	20 (11.4)	0.575
Drug histories				
Aspirin	185 (55.9)	95 (54.3)	90 (57.7)	0.533
β blockers	154 (46.5)	92 (52.6)	62 (39.7)	0.020
Statins	139 (42)	76 (43.4)	63 (40.4)	0.575
ACE-Is	48 (14.5)	30 (17.1)	18 (11.5)	0.148
Nitrate	130 (39.3)	68 (38.9)	62 (39.7)	0.869
Laboratories				
CK-MB (IU/L)	25 (20, 33)	25 (19, 32)	25 (20, 35)	0.135
Troponin I (ng/μL)	0.01 (0.01, 0.2)	0.01 (0.01, 0.1)	0.01 (0.01, 0.3)	0.096
Creatinine (mg/dL)	0.9 (0.8, 1.1)	0.9 (0.8, 1.1)	0.9 (0.8, 1.1)	0.821
Fasting plasma glucose (mg/dL)	95 (86, 121)	93 (85, 109)	101 (87, 128)	0.036
Triglyceride (mg/dL)	134 (94, 178)	125 (90, 169)	146 (96, 182)	0.045
High density lipoprotein (mg/dL)	38 (33, 45)	38 (33, 44)	38 (33, 45)	0.504
Hemoglobin (mg/dL)	13.5±1.8	13.3±1.7	13.8±1.9	0.049
Platelet count (10 ⁹ /L)	210 (181, 253)	197 (168, 227)	232 (198, 271)	<0.001
MPV (fL)	9.6 (9, 10.2)	9.8 (9, 10.4)	9.4 (9, 10)	<0.001
WBC (×10 ³ /μL)	6.8 (5.9, 8)	6 (5, 6.6)	8 (7, 10)	<0.001
WMR	703 (612, 907)	619 (547, 663)	917 (799, 1036)	<0.001
Presentation				
NSTE-MI	41 (12.4)	15 (8.6)	26 (16.7)	0.026
MetS	206 (62.2)	89 (50.9)	117 (75)	<0.0001
Outcomes				
Follow-up duration (month)	24 (23, 25)	24 (23, 25)	24 (23, 25)	0.448
MACE	64 (19.3)	25 (14.3)	39 (25)	0.014

Values are presented as mean (±standard deviation), median (25th and 75th percentiles), and number (percentage). Statistical analyses were performed using Mann-Whitney U test, t-test and Chi-square test. WMR: white blood cell count to mean platelet volume ratio, NYHA: New York heart association, CABG: coronary artery bypass graft surgery, ACE-I: angiotensin-converting enzyme inhibitors, CK-MB: creatine kinase MB isoenzyme, MPV: mean platelet volume, WBC: white blood cell count, NSTEMI: non-ST elevation myocardial infarction, MetS: metabolic syndrome, MACE: major adverse cardiac events

Table 2. Baseline characteristics, laboratories, and clinical outcomes in groups according to MetS status

	Non-MetS (n=125)	MetS (n=206)	p
Baseline characteristics			
Age (year)	59.5±13.6	60.4±11.8	0.520
Gender (male)	97 (77.6)	93 (45.1)	<0.001
Body mass index (kg/m ²)	25 (23, 27.7)	29.5 (27, 32)	<0.001
Waist circumference	89 (83, 95)	102 (92, 110)	<0.001
Systolic blood pressure	130 (120, 140)	140 (130, 155)	<0.001
Diastolic blood pressure	80 (72, 87)	85 (80, 95)	<0.001
NYHA functional class			0.131
Class 1	37 (29.6)	42 (20.4)	
Class 2	14 (11.2)	38 (18.4)	
Class 3	68 (54.4)	118 (57.3)	
Class 4	6 (4.8)	8 (3.9)	
Previous medical histories			
Diabetes mellitus	12 (9.6)	94 (45.6)	<0.001
Hypertension	42 (33.6)	156 (75.7)	<0.001
Dyslipidemia	8 (6.4)	51 (24.8)	<0.001
Smoking	46 (36.8)	41 (19.9)	0.001
Familial history	29 (23.2)	61 (29.6)	0.204
Myocardial infarction	34 (27.2)	52 (25.2)	0.694
CABG	12 (9.6)	29 (14.1)	0.231
Drug histories			
Aspirin	56 (44.8)	129 (62.6)	0.002
β blockers	56 (44.8)	98 (47.6)	0.624
Statins	38 (30.4)	101 (49)	0.001
ACE-Is	13 (10.4)	35 (17)	0.099
Nitrate	40 (32)	90 (43.7)	0.035
Laboratories			
CK-MB (IU/L)	24 (19.5, 32)	25 (20, 33)	0.228
Troponin I (ng/μL)	0.01 (0.01, 0.2)	0.01 (0.01, 0.2)	0.621
Creatinine (mg/dL)	0.9 (0.8, 1)	0.9 (0.8, 1.1)	0.863
Fasting plasma glucose (mg/dL)	89.5 (81.5, 95)	104 (89, 134)	<0.001
Triglyceride (mg/dL)	101.5 (76, 131)	161 (116, 210)	<0.001
High density lipoprotein (mg/dL)	40 (34, 46)	38 (33, 43)	0.022
Hemoglobin (mg/dL)	13.7±1.9	13.4±1.8	0.125
Platelet count (10 ⁹ /L)	200 (169, 228)	220 (185, 261)	<0.001
MPV (fL)	9.7 (9.1, 10.2)	9.5 (8.9, 10.1)	0.073
WBC (×10 ³ /μL)	6.6 (5.7, 7.1)	7.1 (6, 8.9)	<0.001
WMR	670 (591, 758)	762 (631, 954)	<0.001
Presentation			
NSTEMI	15 (36.6)	26 (63.4)	0.868
Outcomes			
Follow-up duration, month	24 (24, 25)	24 (23, 25)	0.136
MACE	23 (18.4)	41 (19.9)	0.737

Values are presented as mean (±standard deviation), median (25th and 75th percentiles), and number (percentage). Statistical analyses were performed using Mann-Whitney U test, t-test and Chi-square test. MetS: metabolic syndrome, NYHA: New York heart association, CABG: coronary artery bypass graft surgery, ACE-I: angiotensin-converting enzyme inhibitors, CK-MB: creatine kinase MB isoenzyme, MPV: mean platelet volume, WBC: white blood cell count, NSTEMI: non-ST elevation myocardial infarction, MACE: major adverse cardiac events

drug histories, conventional cardiovascular risk factors, and biomarkers. Composite MACE was entered as a dependent variable. The WMR value was entered as a categorical variable based on its median value. All statistical analyses were performed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). A two-tailed *p* less than 0.05 was considered statistically significant.

Results

Baseline characteristics and biomarkers

A total of 331 patients (190 males, 57.4%) with mean age of 60±12.5 years were followed and analyzed. All variables were compared between the low WMR group and the high group. Patients in the high WMR group had higher body mass index and waist circumference compared to the low WMR group (*p*=0.049 and *p*=0.024, respectively). The frequency of current smoker in the high WMR group was higher than in the low WMR group (21.7% vs. 31.4%, *p*=0.045). When comparing biomarkers between the two groups, fasting plasma glucose, triglyceride, hemoglobin, platelet count, WBC count, and WMR values in the high WMR group were greater than those in the low WMR group (Table 1). MPV value in the high WMR group was significantly lower than that in the low WMR group (9.8 [9, 10.4] vs. 9.4 [9, 10], *p*<0.001). High WMR patients had a tendency (*p*=0.096) to have higher troponin I compared to low WMR patients. Furthermore, the number of patients with NSTEMI and MetS in the high WMR group was greater than that in the low WMR group (Table 1). The number of MACE incidence at follow-up period in the high WMR group was significantly greater than that in the low WMR group (14.3% vs. 25%, *p*=0.014).

Subgroup analyses

Based on NCEP-ATP III criteria used for identifying MetS, 62.2% of patients in our cohort were diagnosed with MetS. Of measured biomarkers, fasting plasma glucose, triglyceride, platelet count, WBC count, and WMR in MetS patients were significantly higher than those in non-MetS individuals (Table 2). MetS patients had the tendency (*p*=0.073) of having lower MPV values than non-MetS ones. The number of MACE incidence in both groups was comparable (18.4% vs. 19.9%, Table 2).

Another subgroup analysis was performed, in which patients with or without MetS were divided into two groups according to WMR values (WMR<720 vs. WMR≥720, Table 3). When comparing MetS patients according to WMR values, patients in elevated WMR group were associated with more MACE incidence at follow-up (11.2% vs. 26.5%, *p*=0.007). There was no difference between WMR groups regarding the number of patients with NSTEMI (9%

vs. 25.4%, *p*=0.171). Moreover, among patients without MetS, MACE incidence was comparable between WMR groups (17.4% vs. 20.5%, *p*=0.681). The number of patients with NSTEMI in the high WMR group was significantly higher than that in the low WMR group (8.1% vs. 20.5%, *p*=0.049).

Survival analysis

Kaplan-Meier analysis was conducted to compare MACE-free survival between study groups. When comparing patients with or without MetS, there was no difference in MACE-free survival between groups (Fig. 1). Considering all patients, the proportion of patients remaining MACE-free during follow-up was significantly different between the two WMR groups (Fig. 2A). When drawing survival curve for patients with MetS, a significant difference was observed (Fig. 2B). However, such difference was not significant among patients without MetS (Fig. 2C).

Multivariable Cox regression analysis was performed to assess the prognostic value of admission WMR after adjusting for all variables (Table 4). In the first model after entering all patients together, the HR of MACE incidence during follow-up for the high WMR group was 1.856 (95% confidence interval [CI] 1.123–3.067, *p*=0.016). Among patients with MetS, the HR of MACE incidence for the high WMR group was 2.616 (95% CI 1.282–5.339, *p*=0.008). In non-MetS individuals, HR of MACE was 1.035 without significance (95% CI 0.439–2.444, *p*=0.937).

Discussion

WMR as a novel inflammation-based marker has recently been introduced as an independent predictor for long-term cardiovascular events in NSTEMI-ACS patients.¹¹⁾ In this prospective study, for the first time, we demonstrated that elevated admission WMR values could predict MACE incidence at long-term follow-up in NSTEMI-ACS patients. This was more pronounced in the presence of NCEP-ATP III-defined MetS. However, it was not observed among patients without MetS.

MetS is a condition accompanying multiple cardiovascular risk factors. Associated with both type 2 diabetes mellitus and cardiovascular disease, MetS is a major public health concern. However, despite the magnitude of studies concerning MetS pathophysiology and prognosis, it has remained to be investigated more to understand its nature and adverse events.⁹⁾ In a prospective cohort study, Wilson et al.¹²⁾ had shown that MetS is associated with increased risks of type 2 diabetes mellitus and cardiovascular disease during 8-year follow-up period. In terms of pathologic mechanisms involved in MetS pathogenesis, a

Table 3. Baseline characteristics, laboratories, and clinical outcomes in patients with or without MetS

	Non-MetS			MetS		
	WMR<720 (n=86)	WMR≥720 (n=39)	p	WMR<720 (n=89)	WMR≥720 (n=117)	p
Baseline characteristics						
Age (year)	60±12.7	58.4±15.6	0.547	62.2±11.2	59±12	0.044
Gender (male)	62 (72.1)	35 (89.7)	0.028	32 (36)	61 (52.1)	0.210
Body mass index (kg/m ²)	25 (23.5, 27.8)	24.5 (22.6, 27)	0.314	29 (26.8, 32)	30 (27, 32.5)	0.475
Waist circumference	90 (84, 95)	86 (82, 98)	0.522	100 (92, 110)	104 (92, 112)	0.561
Systolic blood pressure	130 (120, 140)	127 (120, 137)	0.253	140 (130, 160)	140 (130, 155)	0.735
Diastolic blood pressure	80 (71, 90)	80 (74, 85)	0.811	85 (80, 93)	85 (80, 97)	0.894
NYHA functional class			0.764			0.457
Class 1	23 (26.7)	14 (35.9)		16 (18)	26 (22.2)	
Class 2	10 (11.6)	4 (10.3)		14 (15.7)	24 (20.5)	
Class 3	49 (57)	19 (48.7)		54 (60.7)	64 (54.7)	
Class 4	4 (4.7)	2 (5.1)		5 (5.6)	3 (2.6)	
Previous medical histories						
Diabetes mellitus	7 (8.1)	5 (12.8)	0.410	43 (48.3)	51 (43.6)	0.500
Hypertension	31 (36)	11 (28.2)	0.390	75 (84.3)	81 (69.2)	0.013
Dyslipidemia	5 (5.8)	3 (7.7)	0.691	25 (28.1)	26 (22.2)	0.334
Smoking	24 (27.9)	22 (56.4)	0.002	14 (15.7)	27 (23.1)	0.191
Familial history	22 (25.6)	7 (17.9)	0.349	25 (28.1)	36 (30.8)	0.676
Myocardial infarction	25 (29.1)	9 (23.1)	0.485	22 (24.7)	30 (25.6)	0.880
CABG	8 (9.3)	4 (10.3)	0.867	12 (13.5)	17 (14.5)	0.831
Drug histories						
Aspirin	42 (48.8)	14 (35.9)	0.178	53 (59.6)	76 (65)	0.427
β blockers	44 (51.2)	25 (64.1)	0.178	50 (56.2)	48 (41)	0.031
Statins	31 (36)	7 (17.9)	0.042	45 (50.6)	56 (47.9)	0.701
ACE-Is	76 (88.4)	36 (92.3)	0.504	20 (22.5)	15 (12.8)	0.068
Nitrate	30 (34.9)	10 (25.6)	0.305	38 (42.7)	52 (44.4)	0.802
Laboratories						
CK-MB (IU/L)	23 (18, 30)	27 (20, 34)	0.250	25.5 (20, 32)	25 (20, 35)	0.549
Troponin (ng/μL)	0.01 (0.01, 0.11)	0.02 (0.01, 0.1)	0.203	0.01 (0.01, 0.1)	0.01 (0.01, 0.3)	0.167
Creatinine (mg/dL)	0.9 (0.8, 1)	0.9 (0.8, 1.2)	0.199	0.9 (0.8, 1.1)	0.9 (0.8, 1.1)	0.454
Fasting plasma glucose (mg/dL)	90 (82, 95)	87 (81, 95)	0.638	102 (89, 134)	104 (91, 137)	0.439
Triglyceride (mg/dL)	100 (76, 130)	103 (79, 132)	0.925	157 (118, 211)	162 (116, 202)	0.857
High density lipoprotein (mg/dL)	40 (34, 46)	39 (36, 46)	0.983	38 (33, 43)	37 (33, 44)	0.767
Hemoglobin (mg/dL)	13.7±1.8	13.7±2	0.910	12.9±1.6	13.7±1.9	0.001
Platelet count (10 ⁶ /μL)	194 (156, 220)	211 (185, 255)	0.022	197 (175, 231)	244 (204, 281)	<0.001
MPV (fL)	9.8 (9.2, 10.3)	9.6 (9, 10)	0.044	9.9 (9.2, 10.5)	9.3 (8.7, 9.8)	<0.001
WBC (×10 ³ /μL)	6 (5.4, 6.7)	7.7 (7, 9.2)	<0.001	5.9 (5.2, 6.6)	8.6 (7.4, 10)	<0.001
WMR	626 (558, 674)	809 (764, 907)	<0.001	613 (547, 656)	940 (818, 1040)	<0.001
Presentation						
NSTEMI	7 (8.1)	8 (20.5)	0.049	8 (9)	18 (15.4)	0.171
Outcomes						
Follow-up duration, month	24 (24, 25)	24 (24, 25)	0.404	24 (23, 25)	24 (23, 24)	0.285
MACE	15 (17.4)	8 (20.5)	0.681	10 (11.2)	31 (26.5)	0.007
Presentation						
NSTEMI	7 (8.1)	8 (20.5)	0.049	8 (9)	18 (15.4)	0.171
Outcomes						
Follow-up duration, month	24 (24, 25)	24 (24, 25)	0.404	24 (23, 25)	24 (23, 24)	0.285
MACE	15 (17.4)	8 (20.5)	0.681	10 (11.2)	31 (26.5)	0.007

Values are presented as mean (±standard deviation), median (25th and 75th percentiles), and number (percentage). Statistical analyses were performed using Mann-Whitney U test, t-test and Chi-square test. MetS: metabolic syndrome, WMR: white blood cell count to mean platelet volume ratio, NYHA: New York heart association, CABG: coronary artery bypass graft surgery, ACE-I: angiotensin-converting enzyme inhibitors, CK-MB: creatine kinase MB isoenzyme, MPV: mean platelet volume, WBC: white blood cell count, NSTEMI: non-ST elevation myocardial infarction, MACE: major adverse cardiac events

cohort study has revealed that inflammation defined by elevated C-reactive protein is correlated with MetS and insulin resistance and that both inflammation and MetS can independently predict new cardiovascular events.⁹⁾ MetS can lead to increased risk of thrombogenesis and platelet aggregation, resulting in vascular complications.¹³⁾ It has been postulated that in patients with MetS, platelet hyperactivity leading to thrombogenesis is the main contributor to insulin resistance, dysglycemia, oxidative stress, and inflammation.¹³⁾ In addition to its effect on platelet activation, MetS also impacts on procoagulant and hypofibrinolytic status associated with inflammatory processes. Therefore, these factors are more likely to predispose individuals to atherosclerosis, venous thrombosis,¹⁴⁾ cardiovascular mortality, and stroke.⁹⁾ In terms of the effect of MetS on the outcomes of ACS patients, some studies have shown that the presence of MetS has been associated with worse prognosis of ACS individuals¹⁵⁾ and patients who are undergoing coronary revascularization.¹⁶⁾ In a large multicenter study, it has been found that MetS patients have similar outcomes as non-MetS patients among NSTEMI-ACS cases.¹⁷⁾ We also demonstrated that there was no significant difference regarding the MACE incidence between MetS patients and non-MetS patients. This might be due to the presence of NSTEMI-ACS in our cohort and heterogeneous population. More prospective large studies are needed to identify the exact mechanisms by which ACS patients with MetS predispose to adverse outcomes.

Regarding the relationship between WBC count and the presence of MetS, some studies have been conducted to assess this association. In some cross-sectional studies,¹⁸⁻²⁰⁾ it has been found that WBC count in MetS patients is significantly higher than that in non-MetS ones, indicating that inflammation-based mechanism is involved in the MetS pathogenesis. However, Kutlucan et al.²¹⁾ have found no difference regarding WBC count levels between patients with MetS and those without MetS. We also demonstrated that WBC count in MetS patients was significantly higher than in non-MetS individuals. Concomitant measurement of other inflammatory markers such as C-reactive protein may be of great value to assess this relationship. In addition to WBC count, platelet count and MPV have also been evaluated with inconsistent results among studies. The majority of cross-sectional studies have demonstrated that increased platelet count is associated with MetS patients.¹⁹⁾²⁰⁾²²⁾²³⁾ In a meta-analysis, platelet count in MetS patients was higher than that in non-MetS patients.²⁴⁾ In contrast, in a cross-sectional investigation, there was no difference in platelet count between MetS and non-MetS individuals.²¹⁾ MPV also has inconsistent results among reports. Park et al.²³⁾ have shown that MPV level is lower in MetS patients than that in non-MetS. However, Tavil et al.²⁵⁾ have found that MPV is elevated in MetS patients compared to that in non-MetS ones with normal coronary angiography. However, Kutlucan et al.²¹⁾ showed no difference in MPV values between patients with MetS and those without MetS. Zaccardi et al.²⁴⁾ demonstrated that MPV levels were comparable between MetS and non-MetS individuals in a meta-analysis. Given these findings, it is more likely that platelet count and MPV levels are in reverse direction among MetS patients, although some studies oppose this hypothesis.

In agreement with the above mentioned results, we found that platelet count was significantly higher in MetS patients compared to that in non-MetS individuals. We found that there was a trend for non-MetS patients to have higher MPV values compared to MetS subjects. These results suggest that WMR might be of great importance in NSTEMI-ACS cases with MetS as an indicator of decreased MPV and elevated WBC. The reason why MPV is lower in MetS patients may be explained by the notion that the degree of inflammation can change the MPV values. In our cohort, we entered NSTEMI-ACS with different pathophysiology from that of ST elevation myocardial infarction, in which elevated MPV have been associated with cardiovascular outcomes.²⁶⁾ In addition, some other factors including lifestyle modification, antihypertensive, lipid-lowering agents, and diet therapies can also affect MPV values.²⁷⁾ Moreover, the different timespan between developing ACS and laboratory testing may influence platelet size, suggesting that MPV may change during the acute-phase reaction. The association between ACS patients with MetS and increased inflammatory




Fig. 1. Kaplan-Meier curve analysis showing the estimated proportion of patients remaining free of MACE incidence during follow-up in MetS vs. non-MetS individuals. MACE: major adverse cardiac events, MetS: metabolic syndrome.




Fig. 2. Kaplan-Meier curve analyses showing the estimated proportion of patients remaining free of MACE incidence during follow-up within (A) all patients together, (B) patients with MetS, and (C) patients without MetS. MACE: major adverse cardiac events, MetS: metabolic syndrome, WMR: white blood cell count to mean platelet volume ratio.

Table 4. Adjusted HR for elevated WMR in relation to composite MACE incidence

	HR	95% CI	p
All patients	1.856	1.123–3.067	0.016
Patients with MetS	2.616	1.282–5.339	0.008
Patients without MetS	1.035	0.439–2.444	0.937

The analysis adjusted for all cardiovascular risk factors and other biomarkers. HR: hazard ratio, CI: confidence interval, MetS: metabolic syndrome

pathways has been shown previously. However, whether such association will certainly result in increased thrombogenicity through elevated MPV remains to be established. It has been shown that both activated and inactivated platelets are involved in leukocyte and platelet conjugation process, a dynamic process in which platelet activation status and leukocytes' adhesion ability will result in different bindings capacity to induce inflammatory and thrombogenicity.²⁸⁾ Large prospective studies with serial MPV measuring will be needed to solve this controversy.

To understand the relations of WBC count and MPV values to MetS, we introduced another novel non-invasive inflammation-based marker of complete blood count named WMR. Based on our findings, WMR was elevated in MetS patients. When comparing WMR groups, $WMR \geq 720$ was associated with higher MetS rates and MACE incidence at long-term follow-up. Furthermore, MACE incidence was significantly higher in the high-WMR group among MetS patients. However, it was not significantly higher in non-MetS patients.

Study limitations

This study had several limitations. First, our study had a small sample size. Secondly, our cohort was derived from a larger group of ACS patients. In addition, we excluded ST elevation myocardial

infarction without specified MetS cases. Hence, we are unable to prevent selection biases. It is possible that other unmeasured confounding factors might have influenced our study findings. Although WMR may be considered as an inflammatory marker, unfortunately, we did not measure other inflammatory markers such as C-reactive protein to show any comparison between WMR and such markers. Finally, our cohort included more unstable angina patients compared to NSTEMI. Some NSTEMI-ACS cases underwent revascularization at the time of this study. Therefore, our findings can be generalizable to NSTEMI-ACS without revascularization. However, our findings can be of great importance among NSTEMI-ACS patients. Future studies will be helpful to show the prognostication of WMR in such cases.

Conclusion

This study showed that elevated admission WMR value was strongly related to the presence of MetS among NSTEMI-ACS individuals. Furthermore, high WMR was associated with increased long-term MACE-free survival in patients with MetS, but not in non-MetS individuals. Further large-scaled studies are needed to clarify this relationship and identify the role of WMR in the risk assessment of ACS patients with metabolic diseases.

Acknowledgments

We acknowledge the contribution of Dr. Leila Taghipour-Sani who cooperated in gathering the primary data for cohort patients.

References

1. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med* 2013;368:2004-13.
2. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. *Circulation* 2003;107:499-511.
3. Margolis KL, Manson JE, Greenland P, et al. Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. *Arch Intern Med* 2005;165:500-8.
4. Dehghani MR, Rezaei Y, Taghipour-Sani L. Superiority of total white blood cell count over other leukocyte differentials for predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome. *Biomarkers* 2014;19:378-84.
5. Davi G, Patrono C. Platelet activation and atherothrombosis. *N Engl J Med* 2007;357:2482-94.
6. Rechciński T, Jasińska A, Foryś J, et al. Prognostic value of platelet indices after acute myocardial infarction treated with primary percutaneous coronary intervention. *Cardiol J* 2013;20:491-8.
7. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet Med* 1998;15:539-53.
8. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. *J Am Coll Cardiol* 2010;56:1113-32.
9. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. *Circulation* 2004;110:380-5.
10. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high Blood cholesterol in adults (Adult Treatment Panel III) final report. *Circulation* 2002;106:3143-421.
11. Dehghani MR, Rezaei Y, Taghipour-Sani L. White blood cell count to mean platelet volume ratio as a novel non-invasive marker predicting long-term outcomes in patients with non-ST elevation acute coronary syndrome. *Cardiol J* 2015.
12. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. *Circulation* 2005;112:3066-72.
13. Suslova TE, Sitozhevskii AV, Ogurkova ON, et al. Platelet hemostasis in patients with metabolic syndrome and type 2 diabetes mellitus: cGMP- and NO-dependent mechanisms in the insulin-mediated platelet aggregation. *Front Physiol* 2015;5:501.
14. Alessi MC, Juhan-Vague I. Metabolic syndrome, haemostasis and thrombosis. *Thromb Haemost* 2008;99:995-1000.
15. Dohi T, Miyauchi K, Kasai T, et al. Impact of metabolic syndrome on 10-year clinical outcomes among patients with acute coronary syndrome. *Circ J* 2009;73:1454-8.
16. Kajimoto K, Kasai T, Miyauchi K, et al. Metabolic syndrome predicts 10-year mortality in non-diabetic patients following coronary artery bypass surgery. *Circ J* 2008;72:1481-6.
17. Mehta RH, Westerhout CM, Zheng Y, et al. Association of metabolic syndrome and its individual components with outcomes among patients with high-risk non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2014;168:182-8.e1.
18. Gharipour M, Ramezani MA, Sadeghi M, et al. Sex based levels of C-reactive protein and white blood cell count in subjects with metabolic syndrome: Isfahan Healthy Heart Program. *J Res Med Sci* 2013;18:467-72.
19. Jesri A, Okonofua EC, Egan BM. Platelet and white blood cell counts are elevated in patients with the metabolic syndrome. *J Clin Hypertens (Greenwich)* 2005;7:705-11; quiz 712-3.
20. Liu H, Hsu CH, Lin JD, et al. Predicting metabolic syndrome by using hematogram models in elderly women. *Platelets* 2014;25:97-101.
21. Kutlucan A, Bulur S, Kr S, et al. The relationship between mean platelet volume with metabolic syndrome in obese individuals. *Blood Coagul Fibrinolysis* 2012;23:388-90.
22. Chen YL, Hung YJ, He CT, et al. Platelet count can predict metabolic syndrome in older women. *Platelets* 2015;26:31-7.
23. Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ. The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: a focus on gender differences. *Platelets* 2012;23:45-50.
24. Zaccardi F, Rocca B, Pitocco D, Tanese L, Rizzi A, Ghirlanda G. Platelet mean volume, distribution width, and count in type 2 diabetes, impaired fasting glucose, and metabolic syndrome: a meta-analysis. *Diabetes Metab Res Rev* 2015;31:402-10.
25. Tavil Y, Sen N, Yazici HU, Hizal F, Abaci A, Cengel A. Mean platelet volume in patients with metabolic syndrome and its relationship with coronary artery disease. *Thromb Res* 2007;120:245-50.

26. Chu SG, Becker RC, Berger PB, et al. Mean platelet volume as a predictor of cardiovascular risk: a systematic review and meta-analysis. *J Thromb Haemost* 2010;8:148-56.
27. Gasparyan AY, Ayzvazyan L, Mikhailidis DP, Kitas GD. Mean platelet volume: a link between thrombosis and inflammation? *Curr Pharm Des* 2011;17:47-58.
28. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Activated and unactivated platelet adhesion to monocytes and neutrophils. *Blood* 1991;78:1760-9.